LUMENThe LuMEn Study: 177Lu-octreotate Treatment Outcome Prediction Using Multimodality Imaging in Refractory Neuroendocrine Tumours.

Fecha de inicio: 1 de mayo de 2013

Inclusion Criteria: Patient-based: Age above or equal to 18 years. Histology-proven advanced GEP-NETs. Disease progression defined as follows (at least one of the following): - Radiological disease progression (according to RECIST 1.1) on an MRI or CT over the last 12 months Or - Disease progression on a somatostatin receptor-imaging, PET/CT or SPECT/CT over the last 12 months [apparition of new lesion(s) or increase in the transaxial plane diameter of more than 30% on the same imaging modality] Or - Both of the following criteria (a+b): clinical progression: sustained (for more than 2 weeks) increase of NET-specific hormonal hypersecretion related symptom frequency by 50% or, sustained (for more than 2 weeks) increase of severity by 1 grade (according to NCI-CTCAE version 4.03). biochemical progression: by increase of NET-specific tumor markers (plasma Chromogranin A, plasma NSE, urine 5-HIAA or other) in two successive measurements. Disease refractory to SSA's and/or standard systemic therapy available in Belgium at the time of inclusion criteria. Long-acting SSAs should be discontinued at least 4 weeks before study treatment start date and, if needed, switched to short-acting analogues which should be stopped 48h before the treatment date. Adequate renal function with GFR ≥ 50 mL/min/1.73m2 (evaluated by 51Cr-EDTA test). Adequate bone marrow function with hemoglobin ≥ 9 g/dL; neutrophil ≥ 1.5·103/μL; platelet count ≥ 100·103/μL. Adequate liver function with total bilirubin ≤ 2 x ULN and transaminases ≤ 5 x ULN, serum albumin > 3 g/dL with normal prothrombin time (> 70%). ECOG Performance Status ≤ 1. Women of childbearing potential and men with partners of childbearing potential must agree to use a highly-effective form of contraception for the duration of study participation and up to six months after the end of the treatment. A pregnancy test (serum) must be performed within 4 weeks prior to inclusion for every female patient of childbearing potential and it must be negative. Patient's written informed consent obtained prior to any study procedure. All necessary baseline procedures should be performed within 4 weeks prior to first 177Lu-octreotate injection (D0). Lesion-based: The patient must have at least one target lesion fulfilling all of the below criteria: On the 68Ga-octreotate PET/CT: tumor uptake higher than the physiological liver uptake (grade III or IV of the Rotterdam visual score) in a lesion with longest transaxial plane diameter ≥20mm (measured on the CT, part of the PET/CT); At least one of these lesions morphologically measurable according to RECIST 1.1 and progressive on the MRI (or CT if MRI is not applicable); Target lesion should not have been previously irradiated. Exclusion Criteria: Resectable tumor with curative intent. Any major surgery within the last 6 weeks prior to inclusion in the study Radiotherapy, chemotherapy, embolization, mammalian target of rapamycin (mTOR)-inhibitors, receptor tyrosine-kinase inhibitors, interferon, or other investigational therapy within the last 12 weeks prior to inclusion in the study. Diffuse bone marrow infiltration on the baseline 68Ga-octreotate PET/CT confirmed by MRI. Prior external beam radiotherapy on kidneys or on more than 25% of bone marrow. Patients with known uncontrolled brain metastases. Patients with a significant medical, neuro-psychiatric, or surgical condition, currently uncontrolled by treatment, which, in the investigator's opinion, may interfere with completion of the study. Pregnant or lactating patients. Women of childbearing potential and men with partners of child-bearing potential refusing an adequate contraception.